Clinical Trial Detail

NCT ID NCT01560416
Title Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant

Ganetespib

Age Groups: adult

Additional content available in CKB BOOST